A growing number of TRP channels are of potential therapeutic interest to treat pain conditions [7,12] Clinical trials with potent, small molecule antagonists targeting thermoTRPs, mainly TRPV1 are on-going for diverse indications encompassing chronic pain, neuropathic pain, and migraine [7,12,212]. The gene discussed is TRPV1; the disease is migraine disorder.